[Clinical efficiency of course and long-term therapy with the angiotensin-converting enzyme inhibitor perindopril in patients with chronic obstructive lung disease and cor pulmonale].
to evaluate the clinical efficiency of course and long-term therapy with the angiotensin-converting enzyme (ACE) inhibitor perindopril in patients with chronic obstructive lung disease (COLD) and chronic cor pulmonale (CCP). Forty patients aged 40 to 56 years (mean 45.0 +/- 2.0 years) who had COLD and CCP were examined. Hemodynamic parameters were recorded by M- and B-mode and Doppler echocardiographies. Addition of perindopil to course therapy in patients with COLD and CCP ameliorated pulmonary hypertension, positively affected central and peripheral hemodynanic parameters, and failed to have a negative impact on external respiratory function and renal and hepatic function. The long-term use of perindopril in individually adjusted doses in the outpatient setting showed pronounced beneficial clinical effects and considerably improved the morphofunctional parameters of the right cardiac cavities and patients' life quality. It is advisable to include the ACE inhibitor perindopril into complex therapy in patients with CCP in order to correct pulmonary and central hemodynamic disorders.